Business Description
Gain Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US36269B1052
Total Employee Number:
21Description
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 24.61 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.6 | |||||
3-Year EPS without NRI Growth Rate | 26.3 | |||||
3-Year FCF Growth Rate | 23.4 | |||||
3-Year Book Growth Rate | -34.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -12.04 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46 | |||||
9-Day RSI | 47.34 | |||||
14-Day RSI | 47.76 | |||||
3-1 Month Momentum % | -11.68 | |||||
6-1 Month Momentum % | -15.12 | |||||
12-1 Month Momentum % | 3.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 4.69 | |||||
Cash Ratio | 4.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.4 | |||||
Shareholder Yield % | -31.41 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -221.45 | |||||
ROA % | -143.54 | |||||
ROIC % | -2341.42 | |||||
3-Year ROIIC % | 35.09 | |||||
ROC (Joel Greenblatt) % | -5990.27 | |||||
ROCE % | -188.11 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.3 | |||||
Price-to-Tangible-Book | 5.3 | |||||
EV-to-EBIT | -2.98 | |||||
EV-to-EBITDA | -3 | |||||
EV-to-Forward-Revenue | 218.02 | |||||
EV-to-FCF | -3.03 | |||||
| Price-to-Net-Current-Asset-Value | 5.47 | |||||
| Price-to-Net-Cash | 6.25 | |||||
Earnings Yield (Greenblatt) % | -33.56 | |||||
FCF Yield % | -25.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GANX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gain Therapeutics Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.58 | ||
| Beta | -0.5642 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.22 | ||
| Volatility % | 116.45 | ||
| 14-Day RSI | 47.76 | ||
| 14-Day ATR ($) | 0.123215 | ||
| 20-Day SMA ($) | 1.803 | ||
| 12-1 Month Momentum % | 3.57 | ||
| 52-Week Range ($) | 1.41 - 4.34 | ||
| Shares Outstanding (Mil) | 42.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gain Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gain Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 109 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 17 days | ||
| General meeting for 2026 | 2026-06-24 08:30 | 1.77 (-3.28%) | ||
| H.C. Wainwright 7(th) Annual Neuro Perspectives Expert Summit | 2026-06-15 07:00 | 1.68 (+1.82%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.82 (-1.62%) | ||
| Annual report for 2025 | 2026-03-26 | 1.96 (+3.70%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 1.96 (+3.70%) | ||
| 38(th) Annual ROTH Conference | 2026-03-23 11:30 | 1.95 (+2.63%) | ||
| Oppenheimer 36(th) Annual Healthcare Life Sciences Conference | 2026-02-25 13:20 | 2.74 (+30.48%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.68 (+7.20%) |
Show
Entries
Gain Therapeutics Inc Frequently Asked Questions
What is Gain Therapeutics Inc(GANX)'s stock price today?
The current price of GANX is $1.75. The 52 week high of GANX is $4.34 and 52 week low is $1.41.
When is next earnings date of Gain Therapeutics Inc(GANX)?
The next earnings date of Gain Therapeutics Inc(GANX) is 2026-08-12 Est..
Does Gain Therapeutics Inc(GANX) pay dividends? If so, how much?
Gain Therapeutics Inc(GANX) does not pay dividend.
Guru Commentaries on NAS:GANX
No articles.
Press Release
Articles on Gain Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers